Stina Mui Singel

3.9k total citations
26 papers, 599 citations indexed

About

Stina Mui Singel is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stina Mui Singel has authored 26 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stina Mui Singel's work include Cancer Treatment and Pharmacology (10 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Advanced Breast Cancer Therapies (7 papers). Stina Mui Singel is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Advanced Breast Cancer Therapies (7 papers). Stina Mui Singel collaborates with scholars based in United States, Spain and South Korea. Stina Mui Singel's co-authors include Kimberly Batten, Crystal Cornelius, Woodring E. Wright, Jerry W. Shay, Steven Gendreau, Lawrence Lum, Isabelle Rooney, Matthew Wongchenko, Cristina Saura and Steven J. Isakoff and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Stina Mui Singel

26 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stina Mui Singel United States	11	336	297	197	138	77	26	599
Vishnu Kumarasamy United States	14	271 0.8×	360 1.2×	258 1.3×	103 0.7×	68 0.9×	22	621
Grit S. Herter-Sprie United States	10	350 1.0×	307 1.0×	103 0.5×	137 1.0×	39 0.5×	14	680
Vernon T. Phan United States	12	583 1.7×	252 0.8×	117 0.6×	164 1.2×	51 0.7×	16	875
Aimee Bence Lin United States	18	622 1.9×	636 2.1×	259 1.3×	144 1.0×	76 1.0×	42	977
Louise Barys Switzerland	8	328 1.0×	157 0.5×	105 0.5×	62 0.4×	69 0.9×	12	575
Shany Koren Switzerland	8	367 1.1×	320 1.1×	82 0.4×	194 1.4×	75 1.0×	9	622
Ka Tat Siu United States	10	335 1.0×	186 0.6×	82 0.4×	105 0.8×	62 0.8×	15	500
Lucia Trandafir Switzerland	11	280 0.8×	247 0.8×	272 1.4×	85 0.6×	37 0.5×	22	634
Jolien Van den Bossche Belgium	14	247 0.7×	307 1.0×	106 0.5×	106 0.8×	71 0.9×	22	541
Ho-June Lee France	3	268 0.8×	267 0.9×	119 0.6×	87 0.6×	46 0.6×	3	491

Countries citing papers authored by Stina Mui Singel

Since Specialization

Citations

This map shows the geographic impact of Stina Mui Singel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stina Mui Singel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stina Mui Singel more than expected).

Fields of papers citing papers by Stina Mui Singel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stina Mui Singel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stina Mui Singel. The network helps show where Stina Mui Singel may publish in the future.

Co-authorship network of co-authors of Stina Mui Singel

This figure shows the co-authorship network connecting the top 25 collaborators of Stina Mui Singel. A scholar is included among the top collaborators of Stina Mui Singel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stina Mui Singel. Stina Mui Singel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Starodub, Alexander, Sung‐Bae Kim, Diwakar Davar, et al.. (2024). TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.. Journal of Clinical Oncology. 42(16_suppl). 2601–2601. 1 indexed citations

Starodub, Alexander, S-B. Kim, Diwakar Davar, et al.. (2023). 1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy. Annals of Oncology. 34. S628–S628. 2 indexed citations

Tannir, Nizar M., Neeraj Agarwal, Sumanta K. Pal, et al.. (2020). PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 38(6_suppl). TPS763–TPS763. 16 indexed citations

Schmid, Peter, Delphine Loirat, Peter Savas, et al.. (2019). Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Research. 79(13_Supplement). CT049–CT049. 42 indexed citations

Oliveira, Mafalda, Cristina Saura, Paolo Nucíforo, et al.. (2019). FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Annals of Oncology. 30(8). 1289–1297. 108 indexed citations

Schmid, Peter, Delphine Loirat, Peter Savas, et al.. (2019). Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Clinical Trials. CT049–CT049. 1 indexed citations

Reck, Martin, Federico Cappuzzo, Delvys Rodríguez‐Abreu, et al.. (2019). 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours. Annals of Oncology. 30. xi46–xi47. 1 indexed citations

Schöffski, Patrick, Sara Cresta, Ingrid A. Mayer, et al.. (2018). A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research. 20(1). 109–109. 67 indexed citations

Liu, Lichuan, Sravanthi Cheeti, Kenta Yoshida, et al.. (2018). Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects. The Journal of Clinical Pharmacology. 58(11). 1427–1435. 29 indexed citations

10.

Oliveira, Mafalda, Cristina Saura, Isabel Calvo, et al.. (2018). Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC). Cancer Research. 78(13_Supplement). CT041–CT041. 3 indexed citations

11.

Dent, Rebecca, Sung‐Bae Kim, Seock‐Ah Im, et al.. (2017). LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 35(15_suppl). 1009–1009. 2 indexed citations

12.

Vuylsteke, Peter, Manon Huizing, Katarína Petráková, et al.. (2016). Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Annals of Oncology. 27(11). 2059–2066. 91 indexed citations

13.

Saura, Cristina, Evandro de Azambuja, Mafalda Oliveira, et al.. (2016). LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.. Journal of Clinical Oncology. 34(15_suppl). TPS613–TPS613. 4 indexed citations

14.

Oliveira, Mafalda, Cristina Saura, Antonio González-Martı́n, et al.. (2015). FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 33(15_suppl). TPS1112–TPS1112. 1 indexed citations

15.

Kim, Sung‐Bae, Antoinette R. Tan, Seock‐Ah Im, et al.. (2015). LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 33(15_suppl). TPS1111–TPS1111. 3 indexed citations

16.

Vuylsteke, Peter, Katarína Petráková, Rebecca Roylance, et al.. (2015). 1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC). European Journal of Cancer. 51. S265–S266. 2 indexed citations

17.

Singel, Stina Mui, Crystal Cornelius, Elma Zaganjor, et al.. (2014). KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer. Neoplasia. 16(3). 247–256.e2. 73 indexed citations

18.

Singel, Stina Mui, Kimberly Batten, Crystal Cornelius, et al.. (2014). Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Research. 16(2). R28–R28. 48 indexed citations

19.

Singel, Stina Mui, Crystal Cornelius, Kimberly Batten, et al.. (2013). A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer. Clinical Cancer Research. 19(8). 2061–2070. 54 indexed citations

20.

Zaganjor, Elma, Jihan K. Osborne, Laura A. Díaz-Martínez, et al.. (2013). Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells. Oncogene. 33(47). 5457–5466. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact